Differential benefit of adjuvant docetaxel-based chemotherapy in patients with early breast cancer according to baseline body mass index

- Desmedt, Christine, Fornili, Marco, Sotiriou, Christos, Piccart, Martine, Biganzoli, Elia, Clatot, Florian, Demicheli, Romano, De Bortoli, Davido, Di Leo, Angelo, Viale, Giuseppe, de Azambuja, Evandro, Crown, John, Francis, Prudence A.

p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial

- Sonnenblick, Amir, Salgado, Roberto, Crown, John, Viale, Giuseppe, Daly, Laura, Javdan, Bahar, Fujisawa, Sho, de Azambuja, Evandro, Lieveke, Ameye, Piccart, Martine, Bromberg, Jacqueline, Sotirou, Christos, Brohee, Sylvain, Zahavi, Tamar, Peretz, Tamar, van den Eynden, Gert, Rouas, Ghizlaine, Salmon, Asher, Francis, Prudence A., Di Leo, Angelo

p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial

- Sonnenblick, Amir, Salgado, Roberto, Crown, John, Viale, Giuseppe, Daly, Laura, Javdan, Bahar, Fujisawa, Sho, de Azambuja, Evandro, Lieveke, Ameye, Piccart, Martine, Bromberg, Jacqueline, Sotirou, Christos, Brohee, Sylvain, Zahavi, Tamar, Peretz, Tamar, van den Eynden, Gert, Rouas, Ghizlaine, Salmon, Asher, Francis, Prudence A., Di Leo, Angelo

HER2 status predicts for upfront AI benefit: a TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2

- Bartlett, John M. S., Ahmed, Ikhlaaq, Brookes, Cassandra L., Forbes, John F., Viale, Giuseppe, Cuzick, Jack, Dowsett, Mitchell, Rea, Daniel W., Regan, Meredith M., Sestak, Ivana, Mallon, Elizabeth A., Dell'Orto, Patrizia, Thürlimann, Beat, Seynaeve, Caroline, Putter, Hein, Van de Velde, Cornelis J. H.

Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer: TEXT and SOFT Trials

- Regan, Meredith M., Francis, Prudence A., Pinotti, Graziella, Price, Karen N., Coates, Alan S., Goldhirsch, Aron, Gelber, Richard D., Pagani, Olivia, Fleming, Gini F., Walley, Barbara A., Viale, Giuseppe, Colleoni, Marco, Láng, István, Gómez, Henry L., Tondini, Carlo

Impact of CYO19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial

- Johansson, Harriet, Gray, Kathryn P., Colleoni, Marco, Rabaglio, Manuela, Price, Karen N., Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Kammler, Roswitha, Bonanni, Bernardo, Walley, Barbara A., TEXT principal investigators,, Pagani, Olivia, Chirgwin, Jaqueline, Francis, Prudence, Regan, Meredith M., Viale, Giuseppe, Aristarco, Valentina, Macis, Debora, Puccio, Antonella, Roux, Susanne, Maibach, Rudolf

Adjuvant ovarian suppression in premenopausal breast cancer

- Francis, Prudence A., Regan, Meredith M., Martino, Silvana, Davidson, Nancy E., Geyer, Charles E., Walley, Barbara A., Coleman, Robert, Kerbrat, Pierre, Buchholz, Stefan, Ingle, James N., Winer, Eric P., Rabaglio-Poretti, Manuela, Fleming, Gini F., Maibach, Rudolf, Ruepp, Barbara, Giobbie-Hurder, Anita, Price, Karen N., Colleoni, Marco, Viale, Giuseppe, Coates, Alan S., Goldhirsch, Aron, Gelber, Richard D., Lang, István Láng, Ciruelos, Eva, Bellet, Meritxell, Bonnefoi, Hervé R., Climent, Miguel A., Da Prada, Gian Antonio, Burstein, Harold J.

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials

- Regan, Meredith M., Pagani, Olivia, Villani, Laura, Pizzolitto, Stefano, Öhlschlegel, Christian, Sessa, Fausto, Peg Cámara, Vicente, Rodríguez Peralto, José Luis, MacGrogan, Gaëtan, Colleoni, Marco, Goldhirsch, Aron, Price, Karen N., Francis, Prudence A., Coates, Alan S., Gelber, Richard D., Viale, Giuseppe, Fleming, Gini F., Walley, Barbara A., Kammler, Roswitha, Dell'Orto, Patrizia, Russo, Leila, Szőke, János, Doimi, Franco

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013

- Goldhirsch, A., Winer, E. P., Bonnefoi, Hervé, Bretel-Morales, Denisse, Burstein, Harold, Cardoso, Fatima, Castiglione-Gertsch, Monica, Colleoni, Marco, Costa, Alberto, Curigliano, Giuseppe, Davidson, Nancy E., Leo, Angelo Di, Coates, A. S., Ejlertsen, Bent, Forbes, John F., Gelber, Richard D., Gnat, Michael, Goldhirsch, Aron, Goodwin, Pamela, Goss, Paul E., Harris, Jay R., Hayes, Daniel F., Hudis, Clifford A., Gelber, R. D., Ingle, James N., Jassem, Jacek, Jiang, Zefei, Karlsson, Per, Loibl, Sibylle, Morrow, Monica, Namer, Moise, Osborne, C. Kent, Partridge , Ann H., Penault-Llorca, Fréderiqué, Piccart-Gebhart, M., Perou, Charles M., Piccart-Gebhart, Martine, Pritchard, Kathleen I., Rutgers, Emiel J. T., Sedlmayer, Felix, Semiglazov, Vladimir, Shao, Zhi-Ming, Smith, Ian, Thürlimann, Beat, Toi, Masakazu, Tutt, Andrew, Untch, Michael, Viale, Giuseppe, Watanabe, Toru, Wilcken, Nicholas, Winer, Eric P., Wood, William C., Senn, H. - J., Albain, Kathy S., André, Fabrice, Bergh, Jonas

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial

- Fernández-Cuesta, Lynnette, Oakman, Catherine, Larsimont, Denis, Francis, Prudence A., Crown, John, Piccart-Gebhart, Martine, Viale, Giuseppe, Leo, Angelo Di, Olivier, Magali, Falagan-Lotsch, Patricia, Smoth, Ke-seay, Quinaux, Emmanuel, Buyse, Marc, Dolci, M. Stella, Azambuja, Evandro De, Hainaut, Pierre, Dell'Orto, Patrizia

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

- Rasmussen, Birgitte B., Regan, Meredith M., Braye, Stephen, Altermatt, Hans J., Gelber, Richard D., Castiglione-Gertsch, Monica, Goldhirsch, Aron, Gusterson, Barry A., Thürlimann, Beat, Coates, Alan S., Viale, Giuseppe, Lykkesfeldt, Anne E., Dell'Orto, Patrizia, Del Curto, Barbara, Henriksen, Katrine L., Mastropasqua, Mauro G., Price, Karen N., Méry, Eliane E., Lacroix-Triki, Magali

Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: Predictive value of centrally reviewed expression of estrogen and progesterone receptors - International Breast Cancer Study Group

- Viale, Giuseppe, Regan, Meredith M., Braye, Stephen, Grigolato, Piergiovanni, Rusca, Tiziana, Gelber, Richard D., Castiglione-Gertsch, Monica, Price, Karen N., Goldhirsch, Aron, Gusterson, Barry A., Coates, Alan S., Maiorano, Eugenio, Mastropasqua, Mauro G., Golouh, Rastko, Perin, Tiziana, Brown, Robert W., Kovacs, Aniko, Pillay, Komala, Ohlschlegel, Christian